Renaissance Technologies LLC Lowers Stock Position in ICU Medical, Inc. $ICUI

Renaissance Technologies LLC cut its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 68.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,309 shares of the medical instruments supplier's stock after selling 24,991 shares during the quarter. Renaissance Technologies LLC's holdings in ICU Medical were worth $1,461,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in ICU Medical by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier's stock valued at $387,313,000 after purchasing an additional 89,755 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of ICU Medical by 4.2% during the 4th quarter. Janus Henderson Group PLC now owns 2,576,756 shares of the medical instruments supplier's stock valued at $367,625,000 after purchasing an additional 103,220 shares during the period. Millennium Management LLC raised its position in shares of ICU Medical by 173.4% during the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier's stock valued at $130,638,000 after purchasing an additional 690,694 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of ICU Medical by 6.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier's stock valued at $127,053,000 after buying an additional 63,026 shares in the last quarter. Finally, State Street Corp boosted its holdings in ICU Medical by 2.8% in the 4th quarter. State Street Corp now owns 942,670 shares of the medical instruments supplier's stock worth $134,491,000 after buying an additional 25,545 shares during the period. Institutional investors own 96.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ICUI shares. Weiss Ratings raised ICU Medical from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, July 23rd. Zacks Research cut ICU Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. BTIG Research lifted their target price on ICU Medical from $170.00 to $200.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Sanford C. Bernstein cut ICU Medical to a "market perform" rating in a report on Monday, June 15th. Finally, Raymond James Financial restated a "strong-buy" rating and issued a $200.00 price target on shares of ICU Medical in a research note on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $192.80.

Insider Activity at ICU Medical

In related news, Director Elisha W. Finney sold 378 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total value of $68,977.44. Following the sale, the director owned 4,871 shares in the company, valued at approximately $888,860.08. The trade was a 7.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Christian B. Voigtlander sold 8,929 shares of the company's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the sale, the chief operating officer directly owned 37,377 shares in the company, valued at approximately $6,837,374.61. The trade was a 19.28% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 11,557 shares of company stock valued at $2,103,579. 2.10% of the stock is owned by corporate insiders.

Key Stories Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Strong earnings and margin expansion support the investment case. ICU Medical’s latest quarterly results exceeded expectations, with EPS of $2.37 versus the $1.91 consensus and revenue of $547.88 million versus estimates of $533.44 million. A recent analysis also highlighted margin expansion and strength in the company’s infusion systems business. ICUI Q2 Deep Dive: Margin Expansion and Infusion Systems Drive Outperformance
• Positive Sentiment: Analysts raised price targets following the results. Needham lifted its target to $187, BTIG raised its target to $200, and Piper Sandler increased its target to $195 while maintaining an overweight rating. The consensus rating remains “Moderate Buy,” with an average price target of $192.80.
• Neutral Sentiment: Institutional ownership remains high. Several smaller investment firms recently initiated or increased positions in ICU Medical, while institutional investors and hedge funds collectively own approximately 96.1% of the shares. The reported short-interest data showed zero shares short, offering little indication of short-selling pressure.
• Negative Sentiment: Multiple insiders sold shares near recent highs. COO Christian B. Voigtlander sold 8,929 shares for approximately $1.63 million, CIO Ben Sousa sold 2,250 shares for about $401,000, and Director Elisha Finney sold 378 shares for roughly $69,000. The sales reduced their respective holdings by approximately 19.3%, 42.3% and 7.2%, potentially raising investor concerns about insider conviction. Top ICU Medical Executive Makes a Notable Move With Company Stock

ICU Medical Trading Down 1.5%

Shares of ICU Medical stock opened at $179.34 on Thursday. ICU Medical, Inc. has a twelve month low of $110.50 and a twelve month high of $192.85. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. The business has a 50-day moving average price of $154.67 and a 200-day moving average price of $141.46. The firm has a market cap of $4.48 billion, a price-to-earnings ratio of 151.98, a PEG ratio of 2.54 and a beta of 0.74.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The company had revenue of $547.88 million during the quarter, compared to analyst estimates of $533.44 million. During the same period in the prior year, the company earned $2.10 earnings per share. The firm's revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities research analysts anticipate that ICU Medical, Inc. will post 6.51 EPS for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source